摘要:
A flat panel display TV stand makes it possible to stably install a TV equipped with a flat panel display (e.g. LCD or PDP) regardless of the type of wall (e.g. concrete wall, gypsum board wall, or wooden wall), on which the TV is to be installed, as well as the size of the TV. The stand can fully support the weight of the TV and hides wires and cables drawn from the TV. This provides an aesthetic appearance. In addition, the stand can additionally accommodate peripheral devices (e.g. DVD player or VCR), which are typically used together with the TV. As such, the stand can be used for various purposes.
摘要:
The present invention relates to a process for the preparation of 4-aminomethyl-3-alkoxyiminopyrrolidine methane-sulfonate, a key intermediate of quinolone antibiotics. According to the process of the present invention, the total number of steps has been shortened to 2-3 steps, the solid separation is not required, and the use of costly chemicals, particularly (BOC)2O (t-butoxycarbonyl anhydride), several organic solvents and reactants, is eliminated.
摘要翻译:本发明涉及制备喹诺酮抗生素关键中间体的4-氨基甲基-3-烷氧基亚氨基吡咯烷甲磺酸盐的方法。 根据本发明的方法,步骤总数已经缩短到2-3个步骤,不需要固体分离,并且使用昂贵的化学品,特别是(BOC)2 O (叔丁氧基羰基酐),几种有机溶剂和反应物。
摘要:
The present invention provides a multilayer-coated stent for controlled drug release, comprising: a first base layer formed on a stent support and made of poly(ethylene-co-vinylacetate) or polystyrene-ethylene-butylene rubber polymer; a second coating layer formed on the first base layer and made of a biocompatible or a bioabsorbable polymer and a drug component; and a third coating layer formed on the second coating layer and made of a biocompatible or a bioabsorbable polymer and a drug component different from the drug component of the second coating layer. The inventive stent can deliver a broad range of therapeutic substances for a long time and prevent the early rapid release of the drug components in blood. Also, unlike the existing drug-coated stents, the inventive stent includes two kinds of drugs complementary to each other, but can optimize the efficacy of the drugs by differentiating the control of drug release according to time.
摘要:
A poly-silicon type thin film transistor substrate includes: a plurality of gate lines and data lines defining a pixel; a pixel electrode in the pixel; a thin film transistor having a gate electrode connected to one of the gate lines, a source electrode connected to one of the data lines, a drain electrode connected to the pixel electrode, and a first active layer of poly-silicon defining a channel between the source electrode and the drain electrode; and at least two storage lines positioned on different sides of the pixel electrode.
摘要:
The present invention discloses a method for fabricating a semiconductor device wherein precursor and deposition conditions of a bit line hard mask nitride film and a spacer nitride film are varied so that the nitride films are formed to have different etching ratios for sufficient protection of the bit line during an SAC process.
摘要:
The present invention provides an organic electroluminescence device. The present invention includes an anode, an organic emitting layer on the anode, and a cathode on the organic emitting layer, wherein the organic emitting layer has a configuration of Formula 1,
摘要:
An organic electroluminescence device is disclosed, to realize improvement of luminance and decrease on driving voltage, which includes an anode, a hole injecting layer, a hole transport layer, an emitting layer, and a cathode, wherein, the hole injecting layer and the hole transport layer are formed of the material expressed by the following chemical formula 1:
摘要:
An assay method for the detection of Factor XIII in plasma is disclosed in which a primary amine derivative of biotin such as preferably 5-(biotinamido) pentylamine is incubated with a glutamine substrate and activated Factor XIII (Factor XIIIa) to form a biotinylated product which may be measured by convention detection assays. In a preferred embodiment, the biotinylated product is bound to a well in a microtiter plate or other solid support and the product is measured by a colorimetric assay which may be read by an automated spectrophotometric plate reader.
摘要:
Human α2-antiplasmin (α2AP) is the major inhibitor of the proteolytic enzyme plasmin that digests fibrin. Two forms of α2AP circulate in human plasma: a 464-residue protein, which we have termed “pro”-form, or α2APpro and an N-terminally-shortened 452-residue “activated”-form, or α2APact. The latter becomes crosslinked to fibrin by activated factor XIII about 5-fold more rapidly than α2APpro and makes fibrin resistant to digestion by plasmin. A new human plasma proteinase has been identified herein that cleaves the Pro12-Asn13 bond of α2APpro to yield α2APact. This enzyme is identified herein as Antiplasmin Cleaving Enzyme (APCE). Novel inhibitors of circulating APCE can diminish α2AP inhibitory capacity within forming fibrin or blood clots thereby making fibrin deposits or blood clots more susceptible to removal by plasmin. Patients who are susceptible to atherosclerotic plaque formation or are susceptible to developing thrombi that compromise organ function will benefit by therapies providing such inhibitors on a long term basis.
摘要:
The present invention relates to furancarbonylguanidine derivatives, a preparation method thereof and a pharmaceutical composition comprising the same. Furancarbonylguanidine derivatives of the present invention inhibit NHE-1 (sodium-hydrogen exchanger isoform 1), which helps recovery of heart function damaged from ischemia/reperfusion and decreases myocardial infarction rate, indicating that they have protective effect on myocardial cells. Thus, furancarbonylguanidine derivatives of the present invention can be effectively used for the prevention and the treatment of ischemic heart diseases such as myocardial infarction, arrhythmia, angina pectoris, etc, and also a promising candidate for a heart protecting agent applied to reperfusion therapy including thrombolytics or cardiac surgery including coronary artery bypass graft, percutaneous transluminal coronary angioplasty, etc.